Cargando…
Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity
Phosphatases of regenerating liver (PRL1–3) are among the most oncogenic protein phosphatases but their mechanism of action is poorly understood. Multiple substrates have been proposed as well as a non-catalytic function regulating magnesium transport. Our recent identification of a catalytically in...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960985/ https://www.ncbi.nlm.nih.gov/pubmed/33268817 http://dx.doi.org/10.1038/s41416-020-01194-9 |
_version_ | 1783665158577455104 |
---|---|
author | Gehring, Kalle Miki, Hiroaki |
author_facet | Gehring, Kalle Miki, Hiroaki |
author_sort | Gehring, Kalle |
collection | PubMed |
description | Phosphatases of regenerating liver (PRL1–3) are among the most oncogenic protein phosphatases but their mechanism of action is poorly understood. Multiple substrates have been proposed as well as a non-catalytic function regulating magnesium transport. Our recent identification of a catalytically inactive PRL mutant that retains oncogenicity in a mouse model promises to resolve the question of whether PRLs act as phosphatases or pseudo-phosphatases in different cancer models. |
format | Online Article Text |
id | pubmed-7960985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-79609852021-12-03 Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity Gehring, Kalle Miki, Hiroaki Br J Cancer Comment Phosphatases of regenerating liver (PRL1–3) are among the most oncogenic protein phosphatases but their mechanism of action is poorly understood. Multiple substrates have been proposed as well as a non-catalytic function regulating magnesium transport. Our recent identification of a catalytically inactive PRL mutant that retains oncogenicity in a mouse model promises to resolve the question of whether PRLs act as phosphatases or pseudo-phosphatases in different cancer models. Nature Publishing Group UK 2020-12-03 2021-03-16 /pmc/articles/PMC7960985/ /pubmed/33268817 http://dx.doi.org/10.1038/s41416-020-01194-9 Text en © Cancer Research UK 2020, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Comment Gehring, Kalle Miki, Hiroaki Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity |
title | Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity |
title_full | Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity |
title_fullStr | Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity |
title_full_unstemmed | Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity |
title_short | Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity |
title_sort | phosphatase, pseudo-phosphatase, or both? understanding prl oncogenicity |
topic | Comment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960985/ https://www.ncbi.nlm.nih.gov/pubmed/33268817 http://dx.doi.org/10.1038/s41416-020-01194-9 |
work_keys_str_mv | AT gehringkalle phosphatasepseudophosphataseorbothunderstandingprloncogenicity AT mikihiroaki phosphatasepseudophosphataseorbothunderstandingprloncogenicity |